Background: Allergic asthma is a chronic airway inflammatory disease involving the complementary actions of innate and adaptive immune responses. Endogenously generated cannabinoids acting via CB2 receptors play important roles in both homeostatic and inflammatory processes. However, the contribution of CB2-acting eicosanoids to the innate events preceding sensitization to the common house dust mite (HDM) allergen remains to be elucidated. We investigated the role of CB2 activation during allergen-induced pulmonary inflammation and natural killer (NK) cell effector function. Methods: Lung mucosal responses in CB2-deficient (CB2 À/À ) mice were examined
reduced numbers of group 2 innate lymphoid cells (ILC2s). Depletion of NK cells restored the allergen responsiveness in the lungs and was associated with elevated ILC2 numbers. Conclusions: Collectively, these results reveal that CB2 activation is crucial in regulating pulmonary NK cell function, and suggest that NK cells serve to limit ILC2 activation and subsequent allergic airway inflammation. CB2 inhibition may present an important target to modulate NK cell response during pulmonary inflammation.
Airborne allergens, including those of the house dust mite (HDM) Dermatophagoides pteronyssinus (Derp), are the most common trigger of asthma, a disease that currently affects 300 million people worldwide (1) . A better understanding of the pathways by which airborne allergens entering the airway elicit immune responses is key to the development of new therapeutic agents. Allergic asthma is a chronic bronchial inflammatory condition, characterized by eosinophilic inflammation, T helper 2 (Th2) cytokine production, mucus hypersecretion, and airway hyper-reactivity and remodeling (2, 3) . A number of innate cells including airway epithelial cells, dendritic cells (DC), macrophages, natural killer (NK) cells, and group 2 innate lymphoid cells (ILC2s) also represent critical components of asthma pathogenesis, although their diverse roles remain to be fully defined. Mature ILC2s, which appear to be enriched in the lung, skin and adipose tissue of mice and humans, release interleukin-13 (IL-13) and IL-5 in response to activation by epithelial cell-derived cytokines IL-25 and IL-33 (4, 5) . ILC2s are found in human respiratory tissue and studies from both human and mouse models of asthma demonstrate a role for these cells in promoting eosinophilic inflammation (6) (7) (8) (9) . Natural killer cells are classically recognized for their ability to identify and kill tumors and virally infected cells (10) . Such reactivity is tightly controlled by an expansive system of activating and inhibiting receptors expressed on the surface of NK cells (11) . Notably, NK cells are regulated by a range of endogenously produced eicosanoids including prostaglandin (PG)D 2 , PGE 2 , and CB2 cannabinoids (12) (13) (14) (15) (16) .
Cannabinoid compounds are derived from the plant Cannabis sativa (marijuana), with the major psychoactive constituent being D 9 tetrahydrocannabinol, but endocannabinoids are also produced endogenously in the brain and immune cells (17) (18) (19) (20) (21) . To date, two types of receptors have been identified that mediate the biological actions of cannabinoids, CB1 and CB2, both coupled to G proteins (20, (22) (23) (24) . While CB1 receptors are primarily found in the brain and neuronal tissue, CB2 receptors are highly expressed by NK cells and other immune cells (16, (22) (23) (24) (25) . Notably, the endogenous ligands for these receptors include arachidonyl ethanolamide, 2-arachidonoylglycerol (2-AG) (18, 19, 26) and these endocannabinoids are eicosanoids derived from arachidonic acid (22) . Eicosanoids, including prostaglandins and cysteinyl leukotrienes, are potent locally acting arachidonic acid-derived lipid mediators that regulate diverse homeostatic and inflammatory processes linked to various diseases and allergic conditions such as asthma (27) . We have previously shown that the eicosanoid PGI 2 regulates lung mucosal innate immunity and allergic inflammation (28 
Methods
Additional details on the methods are provided in the Data S1.
Animals, allergen challenge and pulmonary inflammation
Female and male C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME, USA) and CB2 
Statistical analysis
Data were analyzed using GRAPHPAD PRISM 5.0, La Jolla, CA, USA. Data are presented as mean AE SEM. Results involving two variables were analyzed by two-way ANOVA with a Bonferroni post-test. Data comparing two groups were analyzed using an unpaired t-test where *P < 0.05, **P < 0.01 and ***P < 0.001.
Results
Mice lacking CB2 receptors exhibit elevated numbers of pulmonary NK cells and a defect in HDM-induced airway inflammation S1 ). To assess the impact of the elevated NK cell numbers on lung immunity to an important common aeroallergen, allergic inflammation was induced in the airways of mice by intranasal instillation of HDM allergen extract over a period of 3 weeks. HDM inhalation evoked a pronounced inflammatory response in the lungs of WT mice characterized by a striking elevation in the number of airway eosinophils and lymphocytes, as well as cell-associated EPO levels in the BALF (Fig. 1B) . Consistently, flow cytometric analysis revealed a marked rise in both the number of pulmonary Siglec-F + eosinophils ( Fig. 1C) and CD3 + CD4 + T cells (Fig. 1D ). Moreover, allergen inhalation induced a pronounced increase in peribronchial inflammation and mucus production in these mice (Fig. 1E) . In striking contrast, CB2 À/À mice had severely attenuated allergic inflammation and showed little pulmonary eosinophilia, few airway CD4 + T cells and negligible peribronchial inflammation and mucus secretion after HDM inhalation ( Fig. 1B-E ). Control WT and CB2 À/À mice exposed to PBS did not develop any airway inflammation. Collectively, these results demonstrate that CB2 À/À mice are resistant to the induction of pulmonary inflammation in response to allergen inhalation. To corroborate this phenomenon evident in CB2 À/À mice, we tested the effect of inhibiting the activation of CB2 by endocannabinoids in WT mice using a CB2-specific inverse agonist/antagonist AM630 (30, 31) . C57BL/6 mice were challenged with HDM allergen and either treated with vehicle (HDM group) or the antagonist (HDM + AM630 group) and the effect on allergic inflammation examined. The CB2 antagonist caused a pronounced inhibition of HDM-induced eosinophilic inflammation and cell-associated EPO levels ( Fig. 2A ) and a clear reduction in airway Siglec-F + eosinophil and CD4 + T-cell influx ( Fig. 2B ), peribronchial inflammation and mucus secretion in these mice (Fig. 2C ). Control mice that did not inhale HDM, but inhaled PBS instead or were treated with AM630, had no airway inflammation. In sharp contrast to the antagonist, mice treated with a CB2 selective agonist, HU-308, exacerbated HDM-induced airway eosinophilic inflammation (Fig. S2 ).
CB2
À/À mice exhibit elevated number of IFN-c-producing NK cells and reduced monocyte-derived DC in the lungs after HDM allergen inhalation A prominent observation was that the onset of HDMinduced allergic lung inflammation in WT mice was associated with a pronounced increase in the number of pulmonary MHC-II bright CD11b + CD11c + DC, which was lacking in CB2 À/À mice (Fig. 3A) . The lack of inflammatory DC in HDM-challenged CB2 À/À animals was in marked contrast to the number of pulmonary CD3 À CD19 À NK1.1 + NK cells that were clearly elevated compared to WT counterparts. These lung NK cells were predominantly DX5 + (CD49b) but also expressed NKp46 (Fig. 3B ), NKG2/CD94 and intracellular granzyme A (Fig. S3A ) after HDM exposure, and secreted higher levels of IFN-c in response to in vitro stimulation with anti-NK1.1 mAb (Fig. 3C ) yet produced negligible TNF-a or type 2 cytokines (data not shown). These findings led us to examine whether endocannabinoids directly influence cytokine production by NK cells. Lung NK cells from C57BL/6 mice were stimulated (2 9 10 6 cells/ml) with anti-NK1.1 Ab (20 lg/ml) in the absence (vehicle control) or presence of the cannabinoid 2-AG (2 and 10 lM), and the effect on IFN-c production was determined after culture for 24 h. Intriguingly, 2-AG dose dependently inhibited IFN-c production by activated NK cells (Fig. 3D) , suggesting that CB2-acting endocannabinoids play an important role in suppressing cytokine production by pulmonary NK cells. We next investigated whether CB2 À/À mice had elevated levels of (Fig. 4A) . Control WT or CB2 À/À mice exposed to PBS produced no cytokines. Consistent with the depressed Th2 cytokine production, the level of CCL2, shown to significantly contribute to Th2 polarization (32) , was strikingly impaired in CB2 À/À mice compared to WT animals after HDM inhalation (Fig. 4B ). mice with anti-NK1.1 mAb significantly restored allergeninduced airway eosinophilia and cell-associated EPO expression, IL-13 production (Fig. 6A) , peribronchial inflammation and mucus secretion (Fig. 6B ) to a level similar to WT animals. A modest increase in airway eosinophil influx was also observed in WT mice following treatment with anti-NK1.1 mAb compared to control Ig (Fig. 6A) , presumably reflecting the fewer NK1.1 cells resident in the lungs of these mice. Control WT or CB2 À/À mice and anti-NK1.1-treated controls that did not inhale HDM, but inhaled PBS instead, had no airway eosinophilic inflammation (data not shown for clarity). These results suggest that the increase in allergic 
Discussion
Asthma is characterized by type 2 inflammatory reactions involving the coordination of innate and adaptive immune In the present study, we demonstrated, for the first time, that CB2 activation is critical in the development of airway inflammation in response to inhaled HDM allergen. Mice lacking CB2 receptors, which displayed a pronounced elevation in the number of NK cells in the lungs, were resistant to the development of allergic airway disease evidenced by severely attenuated pulmonary inflammation, eosinophil and CD4 + T-cell infiltration, type 2 cytokine production, and mucus secretion. This phenomenon was corroborated in WT mice by inhibiting CB2 activation using a CB2-specific antagonist, AM630. Treatment of C57BL/6 mice with AM630 caused a pronounced inhibition of HDM-induced (10, 36) . Natural killer cell numbers or responses are often reduced or suppressed during type 2-dominated immune responses such as human asthma (37, 38) . Moreover, our data are consistent with previous findings demonstrating that other eicosanoids, such as PGD 2 and PGE 2 , inhibit human NK cells (12) (13) (14) .
In our study, a crucial finding indicative of the immunoregulatory events operative in CB2 À/À mice was that the preponderance of NK cells in their lungs was correlated with reduced numbers of ILC2s, suggesting that NK cells limit ILC2 responses. This is further supported by the depletion of pulmonary NK cells in these mice, which significantly restored the HDM-induced eosinophilic inflammation, IL-13 production and goblet cell hyperplasia, and was associated with elevated numbers of IL-13-expressing ILC2s. That NK cells suppress lung inflammatory responses to inhaled allergen by inhibiting ILC2 responses is a novel finding. Certainly, mature ILC2s represent a potent and early source of exposure. These results demonstrate that the attenuated inflammatory response in CB2 À/À mice is influenced by elevated numbers of IFN-c-producing NK cells, rather than amplification of the Th1 response. In summary, the present findings reveal a hitherto unsuspected role for CB2 endocannabinoid signaling in modulating lung inflammatory responses to HDM allergen by regulating the function or properties of tissue NK cells and suggest that NK cells serve to restrict ILC2 responses and subsequent allergic airway inflammation. Sciences, NIH, under Grant Number P30GM103338.
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